Literature DB >> 15946138

Outcome of colorectal carcinoma in patients under 40 years of age.

Jen-Tsun Lin1, Wei-Shu Wang, Chueh-Chuan Yen, Jin-Hwang Liu, Mu-Hua Yang, Ta-Chon Chao, Po-Min Chen, Tzeon-Jye Chiou.   

Abstract

AIMS: Colorectal carcinoma in patients under 40 years of age usually has a poor prognosis. Controversies still exist regarding the features and the prognosis of colorectal cancer in young patients.
METHODS: The records of 45 patients with histologically confirmed colorectal carcinoma treated between 1992 and 2002 at the Division of Oncology at Taipei Veterans General Hospital were reviewed. The relevance of sex, duration of symptoms, tumor site, histological type, lymph node involvement, Karnofsky performance status (KPS), carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) levels at the diagnosis and tumor stage to overall survival (OS) were determined by univariate analysis, and their independent significance were tested by multivariate analysis.
RESULTS: Most patients presented with an advanced tumor stage (24% Dukes' C and 66% Dukes' D). Colon carcinoma constituted 76% of the colorectal tumors. Family history was present in two patients and did not affect the OS. Two patients were found to have colon carcinoma during pregnancy. The 5-year survival rate in patients with Stage B, C, and D were 25, 16 and 0%, respectively. With aggressive treatment, patients with early stage carcinoma achieved longer survival. Eleven patients received resection of metastatic carcinoma of the liver, lung and ovary. Adjuvant chemotherapy with irinotecan/5-fluorouracil-based chemotherapy seemed to improve the OS in such patients, though the OS was still poorer than in patients with early stage tumors. In univariate analysis, KPS (P = 0.0001), lymph node involvement (P = 0.0024), CEA (P = 0.0423) and LDH levels (P = 0.0126) at the diagnosis and tumor stage (P = 0.0122) proved to be significant predictors of overall survival. Multivariate analyses revealed that KPS > or =70% (P = 0.007) and normal LDH levels at diagnosis (P = 0.004) were predictive of overall survival in this population.
CONCLUSIONS: The present study shows that performance status and preoperative LDH levels were the major determinants for survival in patients with colorectal carcinoma under 40 years of age and the present series also suggests that surgical resection of metastatic colorectal carcinoma followed by adjuvant chemotherapy might be beneficial in certain patients. The data also suggests that current treatment modalities for young patients with advanced colorectal cancer might not be effective and more effective therapeutic regimens might be needed. Thus, it is important for surgeons to recognize the potential for colorectal cancer in young patients and to take an aggressive approach to the diagnosis and early treatment of the disease. (c) 2005 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946138     DOI: 10.1111/j.1440-1746.2005.03893.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  22 in total

1.  Clinical characteristics and prognosis of young patients with colorectal cancer in Eastern China.

Authors:  Jian-Fei Fu; Yan-Qin Huang; Jiao Yang; Cheng-Hao Yi; Hai-Long Chen; Shu Zheng
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

2.  Despite aggressive histopathology survival is not impaired in young patients with colorectal cancer : CRC in patients under 50 years of age.

Authors:  Vera Simone Schellerer; Susanne Merkel; Silke Christiane Schumann; Anne Schlabrakowski; Thomas Förtsch; Claus Schildberg; Werner Hohenberger; Roland Siegfried Croner
Journal:  Int J Colorectal Dis       Date:  2011-09-01       Impact factor: 2.571

Review 3.  Treatment of colorectal cancer in the elderly.

Authors:  Monica Millan; Sandra Merino; Aleidis Caro; Francesc Feliu; Jordi Escuder; Tani Francesch
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

4.  Colorectal carcinoma in different age groups : a histopathological analysis.

Authors:  Leonardo Maciel da Fonseca; Magda Maria Profeta da Luz; Antônio Lacerda-Filho; Mônica Maria Demas Alvares Cabral; Rodrigo Gomes da Silva
Journal:  Int J Colorectal Dis       Date:  2011-08-16       Impact factor: 2.571

Review 5.  Early-onset colorectal cancer: a separate subset of colorectal cancer.

Authors:  Irene Osorio Silla; Daniel Rueda; Yolanda Rodríguez; Juan Luis García; Felipe de la Cruz Vigo; José Perea
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

6.  Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy.

Authors:  Halka Klement; Brad St Croix; Chloe Milsom; Linda May; Qing Guo; Joanne L Yu; Petr Klement; Janusz Rak
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

7.  Young patients with colorectal cancer have poor survival in the first twenty months after operation and predictable survival in the medium and long-term: analysis of survival and prognostic markers.

Authors:  K K Chan; B Dassanayake; R Deen; R E Wickramarachchi; S K Kumarage; S Samita; K I Deen
Journal:  World J Surg Oncol       Date:  2010-09-15       Impact factor: 2.754

Review 8.  Sporadic carcinoma of the colon-rectum in young patients: a distinct disease? A critical review.

Authors:  Andrea Ciarrocchi; Gianfranco Amicucci
Journal:  J Gastrointest Cancer       Date:  2013-09

9.  Improved survival in an Asian cohort of young colorectal cancer patients: an analysis of 523 patients from a single institution.

Authors:  Min-Hoe Chew; Poh-Koon Koh; Kheng-Hong Ng; Kong-Weng Eu
Journal:  Int J Colorectal Dis       Date:  2009-04-23       Impact factor: 2.571

10.  Clinicopathological characteristics of young patients with sporadic colorectal cancer.

Authors:  Asuka Murata; Takashi Akiyoshi; Masashi Ueno; Yosuke Fukunaga; Satoshi Nagayama; Yoshiya Fujimoto; Tsuyoshi Konishi; Toshiya Nagasaki; Jun Nagata; Riki Ohno; Masami Arai; Toshiharu Yamaguchi
Journal:  Surg Today       Date:  2016-01-08       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.